Craig Slingluff
Expertise in
4
conditions

Dr. Craig Slingluff

General Surgery
UVA Health Emily Couric Clinical Cancer Center
1240 Lee St, 
Charlottesville, VA 
Expertise in
4
conditions
UVA Health Emily Couric Clinical Cancer Center
1240 Lee St, 
Charlottesville, VA 

Overview

Craig Slingluff is a General Surgeon in Charlottesville, Virginia. Dr. Slingluff is highly rated in 4 conditions, according to our data. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Eccrine Porocarcinoma, Neuroendocrine Tumor, and Tissue Biopsy.

His clinical research consists of co-authoring 167 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

General Surgery

Licenses

Surgery in VA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Piedmont
  • HMO
  • POS

Locations

UVA Health Emily Couric Clinical Cancer Center
1240 Lee St, Charlottesville, VA 22908

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Enhanced Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists in Patients With Melanoma
Enhanced Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists in Patients With Melanoma
Enrollment Status: Completed
Publish Date: July 16, 2024
Intervention Type: Drug
Study Drugs: 6MHP, NeoAg-mBRAF, PolyICLC, CDX-1140
Study Phase: Phase 1/Phase 2
Open Label, Randomized, Phase I/II Study of a Long Peptide Vaccine Plus TLR Agonists for Resected Stage IIb-IV Melanoma. (MEL60)
Open Label, Randomized, Phase I/II Study of a Long Peptide Vaccine Plus TLR Agonists for Resected Stage IIb-IV Melanoma. (MEL60)
Enrollment Status: Completed
Publish Date: February 28, 2024
Intervention Type: Other, Biological
Study Drug: Peptide Vaccine (LPV7) + Tetanus Peptide
Study Phase: Phase 1/Phase 2
A Trial to Evaluate the Immunogenicity and Safety of a Melanoma Helper Peptide Vaccine Plus Novel Adjuvant Combinations (MEL63)
A Trial to Evaluate the Immunogenicity and Safety of a Melanoma Helper Peptide Vaccine Plus Novel Adjuvant Combinations (MEL63)
Enrollment Status: Terminated
Publish Date: October 30, 2023
Intervention Type: Drug, Biological
Study Phase: Phase 1/Phase 2
A Trial to Evaluate the Safety, Immunogenicity, and Clinical Activity of a Helper Peptide Vaccine Plus PD-1 Blockade
A Trial to Evaluate the Safety, Immunogenicity, and Clinical Activity of a Helper Peptide Vaccine Plus PD-1 Blockade
Enrollment Status: Completed
Publish Date: August 25, 2023
Intervention Type: Drug, Biological
Study Phase: Phase 1/Phase 2
Analysis of the Kinetics and Effects of Vemurafenib + Cobimetinib on Intratumoral and Host Immunity in Patients With Advanced BRAFV600 Mutant Melanoma: Implications for Combination With Immunotherapy
Analysis of the Kinetics and Effects of Vemurafenib + Cobimetinib on Intratumoral and Host Immunity in Patients With Advanced BRAFV600 Mutant Melanoma: Implications for Combination With Immunotherapy
Enrollment Status: Terminated
Publish Date: February 26, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Pilot Trial of an Indoleamine 2,3, Dioxygenase-1 (IDO1) Inhibitor (INCB024360) Plus a Multipeptide Melanoma Vaccine (MELITAC 12.1) in Patients With Advanced Melanoma
A Phase II Pilot Trial of an Indoleamine 2,3, Dioxygenase-1 (IDO1) Inhibitor (INCB024360) Plus a Multipeptide Melanoma Vaccine (MELITAC 12.1) in Patients With Advanced Melanoma
Enrollment Status: Completed
Publish Date: June 08, 2018
Intervention Type: Biological, Drug
Study Phase: Phase 2
This is an Open-label, Phase II Study of a Vaccine Comprising Melanoma Peptides and a Tetanus Helper Peptide, Administered in GM-CSF-in-adjuvant. Patients Will be Randomized to Receive One of Two Different Vaccine Regimens. Patients Will be Stratified by Stage of Disease (IIB vs. III vs. IV).
This is an Open-label, Phase II Study of a Vaccine Comprising Melanoma Peptides and a Tetanus Helper Peptide, Administered in GM-CSF-in-adjuvant. Patients Will be Randomized to Receive One of Two Different Vaccine Regimens. Patients Will be Stratified by Stage of Disease (IIB vs. III vs. IV).
Enrollment Status: Completed
Publish Date: May 02, 2018
Intervention Type: Biological
Study Phase: Phase 2
View 6 Less Clinical Trials

167 Total Publications

Antibody Responses to Melanoma Helper Peptide Vaccines May Enhance Antigen Opsonization Through Formation of Immune Complexes and are Modulated by Vaccine Adjuvants.
Antibody Responses to Melanoma Helper Peptide Vaccines May Enhance Antigen Opsonization Through Formation of Immune Complexes and are Modulated by Vaccine Adjuvants.
Journal: bioRxiv : the preprint server for biology
Published: December 15, 2025
Similar Doctors
Expertise in
14
conditions
Dr. Leora Yarboro
General Surgery
Expertise in
14
conditions
Dr. Leora Yarboro
General Surgery

UVA Health Heart And Vascular Center

1215 Lee St Fl 2, 
Charlottesville, VA 
 (1.2 miles away)
434-243-1000
Languages Spoken:
English
See accepted insurances

Leora Yarboro is a General Surgeon in Charlottesville, Virginia. Dr. Yarboro is highly rated in 14 conditions, according to our data. Her top areas of expertise are Mitral Valve Regurgitation, Aortic Dissection, Aortic Valve Stenosis, Heart Bypass Surgery, and Coronary Artery Bypass Graft (CABG).

Expertise in
22
conditions
Dr. Bruce D. Schirmer
General Surgery | Colorectal Surgery
Expertise in
22
conditions
Dr. Bruce D. Schirmer
General Surgery | Colorectal Surgery

University Of Virginia Physicians Group

1215 Lee St, 
Charlottesville, VA 
 (0.1 miles away)
434-243-6868
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Bruce Schirmer is a General Surgeon and a Colorectal Surgeon in Charlottesville, Virginia. Dr. Schirmer is highly rated in 22 conditions, according to our data. His top areas of expertise are Hernia, Obesity, Malnutrition, Gastric Bypass, and Sleeve Gastrectomy. Dr. Schirmer is currently accepting new patients.

Expertise in
19
conditions
Dr. Philip W. Smith
General Surgery
Expertise in
19
conditions
Dr. Philip W. Smith
General Surgery

University Of Virginia Physicians Group

1 Hospital Dr, Fl 4, 
Charlottesville, VA 
 (0.2 miles away)
434-924-5314
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Philip Smith is a General Surgeon in Charlottesville, Virginia. Dr. Smith is highly rated in 19 conditions, according to our data. His top areas of expertise are Hyperparathyroidism, Familial Isolated Hyperparathyroidism, Parathyroid Hyperplasia, Parathyroidectomy, and Thyroidectomy. Dr. Smith is currently accepting new patients.

Frequently Asked Questions about Dr. Craig Slingluff

How do I make an appointment with Dr. Craig Slingluff?

You can book an appointment with Dr. Craig Slingluff by calling their office at 434-924-9333. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Craig Slingluff a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Craig Slingluff is classified as an Elite expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Craig Slingluff specialize in?

While Dr. Craig Slingluff is a General Surgery, they have specific expertise in Melanoma, Merkel Cell Carcinoma, and Eccrine Porocarcinoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within General Surgery.

Does Dr. Craig Slingluff participate in research or clinical trials?

Yes. Dr. Craig Slingluff has published 167 articles and abstracts on conditions like Melanoma. You can view a list of Dr. Craig Slingluff's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Craig Slingluff accept my insurance?

Dr. Craig Slingluff accepts most major insurance plans, including HealthKeepers and Humana. We recommend calling the office directly at 434-924-9333 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Slingluff's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile